Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2025, and refined full year 2025 financial guidance.

In a Dutch city famous for the treaty that led to the creation of the European Union, delegates gathered at a conference to discuss recent advances in the chemistry ...

Good morning, everyone. My name is Dina Elmonshed, one of the U.S. biotech analysts here at UBS. And joining me today is the President and CEO of Vertex Pharmaceuticals, Reshma Kewalramani. Thank you ...

Oh no! It’s happening again. I’m beginning to appreciate a design that I earlier just couldn’t wrap my head around. New shapes, forms and proportions that initially looked awkward are slowly starting ...

Dezeen Showroom: from wellbeing-enhancing office pods to products that covertly control noise, the following pieces are ...

The startup is advancing a drug licensed from China’s Hengrui Pharma that it claims could be “best-in-class” among a group of ...

KING OF PRUSSIA, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) ("Vertex” or the "Company”), a leading global provider of indirect tax solutions, today announced financial results ...

Apacer (TWSE: 8271), a global leader in industrial memory and storage solutions, will showcase its latest innovations at embeddedworld North America 2025. Visitors will explore Apacer's advancements ...